The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Sprycel (Bristol-Myers Squibb)
D+Q is the most scientifically grounded senolytic intervention in existence. It is also the only compound in this book that genuinely requires a physician to use safely. Those two facts coexist without contradiction.
The central tension resolved: Dasatinib + Quercetin is not a community invention based on speculative biology. It was developed by Mayo Clinic researchers, backed by rigorous preclinical evidence, moved into humans through a systematic clinical trial program, and has produced the first direct tissue evidence that a pharmacological intervention reduces senescent cell burden in living humans. This is landmark science. The Geroscience Hypothesis — that clearing senescent cells improves human healthspan — has received its first human confirmation from this research program. No other senolytic combination has this evidence base. The community is correct to take D+Q seriously.
The problem is the gap between the clinical trial context and community self-administration. In the clinical trials: patients were selected by cardiologically appropriate QT intervals; CBC confirmed no baseline cytopenias; medication lists were reviewed for CYP3A4 interactions; physicians were available when the one SAE occurred. In community use: typically none of these safeguards exist. Dasatinib is a prescription oncology drug with FDA-labeled warnings for pleural effusion, QT prolongation, myelosuppression, and pulmonary arterial hypertension. The intermittent senolytic protocol has substantially less risk than chronic CML dosing. But 'substantially less than chemotherapy' and 'safe without monitoring' are not the same statement.
The healthy aging application — the community's primary motivation — is the most biologically compelling and least clinically validated aspect of D+Q use. The mechanism supports it perfectly: healthy middle-aged adults do accumulate senescent cells with age; clearing them should reduce chronic SASP-driven inflammation; the cascade of benefits documented in disease populations should apply, likely in attenuated form, in lower-burden healthy populations. Whether it does — and how much — requires clinical trials in healthy adults that do not yet exist.
In 2015, the Kirkland lab at the Mayo Clinic published a paper in Nature Medicine that changed the aging field. They had demonstrated, for the first time, that clearing senescent cells from living mice — using a genetic system that made senescent cells eliminate themselves on command — extended healthy lifespan, delayed the onset of age-related pathologies, and improved physical function in already-aged animals. The implication was clear: the accumulation of senescent cells is not merely a correlate of aging. It is a driver. Eliminate the cells, and aging slows.
The next question was: can you do this pharmacologically, without a genetic switch? The same year, Kirkland's group published the answer. Testing a library of compounds against senescent cells in culture, they identified Dasatinib and Quercetin — an FDA-approved leukemia drug and a dietary flavonoid — as compounds that selectively killed senescent cells while leaving non-senescent cells largely unaffected. The selectivity made sense mechanistically: senescent cells upregulate pro-survival pathways (BCL-2 family members, PI3K/Akt/mTOR, HIF-1α) that protect them from their own apoptotic environment. Dasatinib inhibits multiple tyrosine kinases including some that support these pro-survival networks. Quercetin inhibits PI3K/Akt, MDM2, BCL-2, BCL-XL, and other pro-survival pathways. Administered together, the two compounds disable the survival defenses that senescent cells depend on, leaving them vulnerable to the apoptotic signals they had been resisting.
The D+Q combination was identified specifically because each compound had senolytic activity against different cell types. Dasatinib preferentially eliminated senescent human preadipocytes (fat cell precursors) and mouse bone marrow-derived mesenchymal stem/stromal cells. Quercetin was more effective against senescent human umbilical vein endothelial cells (HUVECs), preadipocytes, and other cell types. Together, they covered a broader range of senescent cell populations than either alone. The combination was not accidental — it emerged from a systematic screen designed to find compounds with complementary senolytic profiles.
Animal experiments followed. D+Q administration to old mice improved physical function, reduced frailty, and extended healthy lifespan. In mice made frail by radiation treatment, D+Q strengthened them. In mice modeling accelerated aging (with transplanted senescent cells), D+Q reversed aspects of the dysfunction. The preclinical results were among the most dramatic in the longevity field — not because of modest biomarker improvements, but because of functional, physical, and lifespan outcomes.
Then the Mayo Clinic group did what almost no other longevity researcher had done: they moved it into humans. An open-label Phase 1 pilot study in patients with idiopathic pulmonary fibrosis — a fatal, senescence-associated lung disease — administered three weeks of D+Q (Dasatinib 100 mg + Quercetin 1,250 mg, three consecutive days per week). The results, published in EBioMedicine in 2019, showed improved physical function (6-minute walk test, gait speed, grip strength) in patients with a uniformly progressive fatal disease. It was the first human evidence that a senolytic intervention could improve function in a senescence-driven disease.
A second pilot study, in patients with diabetic kidney disease (DKD), published simultaneously in the same journal, provided something the IPF study could not: direct tissue evidence. Adipose and skin biopsies before and after D+Q treatment showed statistically significant reductions in senescent cell markers — p16, p21, senescence-associated β-galactosidase — in human tissue. This was the first peer-reviewed study to directly demonstrate that a pharmacological intervention decreases senescent cell burden in humans. The Geroscience Hypothesis — that removing senescent cells improves human healthspan — had taken its first confirmed step from animal model to human tissue evidence.
THE CENTRAL TENSION
Dasatinib + Quercetin is the most evidence-backed senolytic combination in existence. It has produced human tissue evidence of senescent cell clearance, functional improvements in disease populations, and an ongoing clinical trial program across multiple indications. It is also the only compound in this book that requires a physician's prescription to access legally, carries cardiac and pulmonary toxicity risks documented in its FDA labeling, has significant drug interactions through CYP3A4, and mandates baseline ECG and CBC monitoring in clinical settings. The community is using this combination without prescriptions, without ECGs, without drug interaction reviews, and without physician oversight. The clinical trial setting provides safety monitoring that makes D+Q manageable. Community self-administration removes that safety infrastructure while retaining the risk profile.
The D+Q combination was identified because the two compounds have different senolytic activity profiles across cell types. Systematic testing by the Kirkland group showed: Dasatinib alone was most effective for senescent human preadipocytes and mouse bone marrow-derived mesenchymal stromal cells. Quercetin alone was most effective for senescent human umbilical vein endothelial cells (HUVECs) and certain other endothelial and epithelial cell types. Together, D+Q showed additive to synergistic senolytic activity across a broader range of senescent cell types than either compound alone. This complementarity — not direct synergy at the receptor level but complementary cell-type coverage — is the specific pharmacological rationale for the combination.
Beyond cell-type coverage, the two compounds also address overlapping but distinct molecular targets. Dasatinib's primary contribution: tyrosine kinase inhibition (PDGFR, SRC kinases, BCR-ABL in the context of senescent cells) that disrupts the specific kinase-dependent survival signaling of certain senescent cell populations. Quercetin's primary contribution: direct BCL-2/BCL-XL inhibition and PI3K/Akt suppression that addresses the general anti-apoptotic armoring across a broader range of cell types. Together: more complete coverage of the pro-survival landscape that protects diverse senescent cell populations.
The clinical trial literature reports no direct pharmacokinetic or pharmacodynamic interaction between Dasatinib and Quercetin — they do not compete for the same metabolic enzyme, they do not affect each other's plasma levels, and there are no documented adverse interaction signals from the trials. This is important because Quercetin is a modest CYP3A4 inhibitor itself — but at the doses used, this has not been documented to significantly affect Dasatinib exposure in clinical practice. The combination is safe from a direct drug-drug interaction standpoint.
To understand why D+Q matters and why it does what it does, cellular senescence biology needs to be established before the compounds. Senescence is the mechanism; D+Q is the intervention.
Cellular senescence is an irreversible cell cycle arrest that occurs in response to various cellular stresses: telomere shortening (after extensive cell divisions), DNA damage, oncogene activation, oxidative stress, and mitochondrial dysfunction. A senescent cell stops dividing but does not die — it enters a stable, metabolically active state that serves as a tumor suppressor mechanism (preventing damaged cells from proliferating into cancers). This is senescence's essential physiological function, and it is genuinely beneficial in acute contexts. The problem is what senescent cells do if they accumulate, which they increasingly do with aging.
Senescent cells acquire a Senescence-Associated Secretory Phenotype (SASP) — they secrete a cocktail of pro-inflammatory cytokines (IL-1α, IL-6, IL-8), chemokines (CXCL1, CXCL10), matrix metalloproteinases (MMP3, MMP9), and growth factors (VEGF, HGF) that profoundly affect the surrounding tissue microenvironment. The SASP recruits immune cells (which ordinarily clear senescent cells in young tissue but do so less efficiently with age), promotes local inflammation, disrupts tissue architecture through MMP activity, promotes fibrosis, impairs stem cell function, and — crucially — can induce senescence in nearby normal cells (paracrine senescence spreading). A senescent cell is not merely a dormant cell waiting to be eliminated — it is an active driver of local pathology.
Senescent cells accumulate with age because two balancing forces shift: the rate of senescent cell induction increases (more accumulated DNA damage, more dysfunctional mitochondria, more oncogenic stress), and the rate of immune-mediated clearance decreases (immunosenescence impairs the NK cell and macrophage activity that clears senescent cells in young tissue). The accumulation is documented across multiple human tissue types and multiple species. In adipose tissue, brain, kidney, liver, lung, and skin, senescent cell burden increases measurably with aging. The tissue consequences of this accumulation — SASP-driven chronic inflammation, impaired stem cell function, structural breakdown — are consistent with the pathological features of aging and age-related disease.
If senescent cell accumulation drives aging pathology, eliminating those cells should reduce that pathology. This is the Geroscience Hypothesis at its most direct: remove the cells driving the aging-like tissue changes, and the tissue changes should improve. The challenge: you cannot just non-specifically kill cells — senescent cells coexist in the same tissues as healthy cells performing essential functions. Selectivity is the entire pharmacological problem. Senolytics solve it by targeting the specific survival mechanisms that senescent cells uniquely depend on — the mechanisms that allow them to resist the apoptotic environment that their own SASP creates. Dasatinib and Quercetin hit those survival mechanisms. Normal cells that depend on these same pathways are also affected, which is why the senolytic dose is kept low and the schedule is intermittent — just enough to destabilize the senescent cell survival networks without chronically suppressing them in normal tissues.
Dasatinib (Sprycel, Bristol-Myers Squibb) is an oral small-molecule BCR-ABL and SRC family kinase inhibitor. FDA-approved since 2006 for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Molecular weight 488 Da. The approved CML dose is 100 mg once daily, taken chronically. The senolytic dose is the same mg per day (100 mg) but administered for only 3 consecutive days rather than daily indefinitely — a fundamentally different pharmacological context.
Dasatinib's ability to kill senescent cells comes from its broad tyrosine kinase inhibition profile — it inhibits not only BCR-ABL (the target for CML) but also: PDGFR (platelet-derived growth factor receptor) and SRC family kinases, which support the PI3K/Akt pro-survival pathway in senescent preadipocytes; ephrin receptor kinases, which are upregulated in some senescent cell types; and multiple additional kinases that contribute to the pro-survival networks senescent cells depend on. By disabling these tyrosine kinase-dependent survival pathways, Dasatinib tips the balance toward apoptosis in cells (senescent cells) that are already under apoptotic pressure from their own DNA damage and oxidative stress — while normal cells that have intact repair mechanisms and survival redundancy are more resilient.
DASATINIB IS A PRESCRIPTION DRUG — NOT A SUPPLEMENT
This is the most important regulatory fact in this chapter. Dasatinib requires a physician's prescription in the United States, European Union, United Kingdom, Canada, Australia, and most countries where it is available. The only legal way to obtain it in these jurisdictions is through a licensed prescriber for an approved indication (CML or Ph+ ALL). The community obtains it from: international online pharmacies (legal gray area for personal importation in the US; prescription still technically required); compounding pharmacies (requires prescription in the US); and occasionally from physicians who prescribe off-label (uncommon but exists in progressive longevity medicine practices). None of these pathways provides the medical monitoring infrastructure that the clinical trials used.
Oral bioavailability: approximately 14-34% (variable; CYP3A4-dependent first-pass metabolism). Time to peak plasma concentration: 0.5-3 hours. Half-life: 3-5 hours. Protein binding: 96%. Metabolism: primarily via CYP3A4; minor contributions from CYP3A5 and FMO3. The CYP3A4 metabolism is the critical drug interaction vulnerability — anything that inhibits CYP3A4 will substantially increase Dasatinib plasma levels (increasing toxicity risk); anything that induces CYP3A4 will reduce levels (reducing efficacy). This is documented in the prescribing information with a long list of contraindicated or cautioned co-medications.
CYP3A4 INTERACTIONS — WHY THIS MATTERS FOR THE LONGEVITY COMMUNITY
CYP3A4 is the enzyme that metabolizes Dasatinib. Strong CYP3A4 inhibitors dramatically increase Dasatinib plasma levels — potentially turning a safe senolytic dose into a toxic dose. STRONG CYP3A4 INHIBITORS to be aware of: ketoconazole (antifungal), itraconazole, clarithromycin, erythromycin, azithromycin (partially), ritonavir and other HIV antiretrovirals, grapefruit juice (yes — grapefruit juice is a clinically relevant CYP3A4 inhibitor). MEDICATIONS IN THE LONGEVITY COMMUNITY: Some nootropic supplements, BPC-157 itself has not been characterized for CYP3A4 effects, but the broader supplement ecosystem contains compounds that can affect CYP3A4. MEDICATIONS IN THE GENERAL POPULATION: Common statins (simvastatin, atorvastatin), calcium channel blockers, some antidepressants (fluoxetine), antifungals, and antibiotics can all affect CYP3A4. A community user on any CYP3A4-affecting medication who adds Dasatinib without checking interactions could experience dramatically elevated Dasatinib levels. This is not a theoretical concern — it is the reason the clinical trials required medication review before enrollment.
Quercetin is a naturally occurring flavonoid — a polyphenolic compound found in apples, onions, berries, capers, and many other fruits and vegetables. It is widely available as an OTC dietary supplement, FDA GRAS status, no prescription required. The standard commercial forms: quercetin dihydrate (most common), quercetin phytosome (lipid complex for improved bioavailability), quercetin glycosides (e.g., isoquercetin — a glycosylated form with substantially better bioavailability). Molecular weight 302 Da (quercetin aglycone). Important: quercetin has very poor and variable bioavailability in the standard quercetin aglycone/dihydrate form — typically 0-17% absorption. Isoquercetin and quercetin phytosome formulations have substantially improved bioavailability.
Quercetin inhibits multiple pro-survival pathways that senescent cells depend on: PI3K/Akt (reduces senescent cell resistance to apoptosis); BCL-2 and BCL-XL (direct inhibition of these anti-apoptotic proteins reduces the apoptotic threshold in senescent cells); MDM2 (which normally inhibits p53 — reducing MDM2 allows p53-mediated apoptosis to proceed in cells that have been holding it in check); and HIF-1α (hypoxia-inducible factor, involved in senescent cell survival under metabolic stress). The breadth of quercetin's senolytic target profile makes it complementary to Dasatinib: the two compounds together cover more of the pro-survival landscape than either alone, which is why the D+Q combination is more broadly active across different senescent cell types.
Beyond senolytics, quercetin has multiple documented biological activities that are relevant to the broader longevity context. CD38 inhibition: quercetin inhibits CD38, the enzyme that degrades NAD+ (relevant to the NAD+ chapter — CD38's age-related upregulation is a major driver of NAD+ decline; quercetin as part of a NAD+ restoration stack has mechanistic logic). Anti-inflammatory: quercetin reduces NF-κB activation and reduces production of pro-inflammatory cytokines — effects that partially overlap with but are distinct from its senolytic effects. Antioxidant: direct radical scavenging and upregulation of endogenous antioxidant systems. These additional mechanisms mean quercetin as a standalone supplement (without Dasatinib) has an independent evidence base for various applications — the senolytic function is just one dimension of what it does.
Standard quercetin dihydrate (the most commonly sold form) has poor oral bioavailability — approximately 0-17% absorption. The clinical trials used quercetin at doses of 1,000-1,250 mg/day precisely because standard quercetin requires high doses to achieve meaningful plasma concentrations. Isoquercetin (quercetin 3-glucoside) has dramatically better bioavailability — approximately 80% or more — because intestinal epithelial cells express the sodium/glucose co-transporter SGLT1, which actively transports the glucose-conjugated form. Quercetin phytosome (lecithin-complexed quercetin) also substantially improves bioavailability through lipid-mediated absorption. A community user taking 500 mg of standard quercetin dihydrate may achieve plasma concentrations comparable to a clinical trial participant taking 1,000 mg, or they may achieve much less — formulation and individual GI transit variables create wide variation. If using standard quercetin, use 1,000-1,250 mg/day matching the clinical trial doses. If using isoquercetin or phytosome, lower doses may be equivalent.
D+Q has more human clinical trial evidence than any other senolytic intervention. This evidence is real, from rigorous academic institutions, and landmark for the aging field. It is also preliminary, from small trials in specific pathological populations, and does not validate the community's primary use case.
Baker et al. (Nature, 2011) [1]: First demonstration that clearing senescent cells in INK-ATTAC transgenic mice extends healthspan. Not D+Q specifically, but established that clearing senescent cells has functional consequences. Zhu et al. (Aging Cell, 2015) [2]: D+Q identified as senolytic in systematic screen; selective senescent cell killing in multiple cell types; improved physical function in aged and radiation-damaged mice. Multiple subsequent independent labs have confirmed D+Q senolytic activity in various mouse models. Grade B: multiple independent labs; well-replicated preclinical findings.
Justice et al. (EBioMedicine, 2019) [3]: 14 patients with IPF. D+Q (Dasatinib 100 mg + Quercetin 1,250 mg) for 3 consecutive days/week for 3 weeks. Primary outcome: physical function. Results: significant improvements in 6-minute walk distance, usual gait speed, short physical performance battery, 5-times sit-to-stand time, and grip strength. No control group — open-label limitation. But IPF is a uniformly progressive fatal disease; improvements in a clinical course that typically only worsens are biologically meaningful. SASP factors in blood tended to decrease. Grade B: real human evidence; first human senolytic trial; open-label limitation; small n; IPF-specific population.
Hickson et al. (EBioMedicine, 2019) [4]: 9 patients with diabetic kidney disease (DKD). D+Q 100 mg/1000 mg for 3 consecutive days. Primary outcome: senescent cell markers in adipose tissue and skin biopsies. Results: Adipose tissue — decreased p16(INK4a) (−50±28%), p21 (−35±14%), and senescence-associated β-galactosidase activity (−10±9%). Skin — decreased p16 (−26±9%) and decreased SASP factors in plasma. THIS IS THE MOST IMPORTANT FINDING IN THE D+Q HUMAN EVIDENCE BASE: direct tissue evidence that a senolytic intervention reduces senescent cell burden in human tissue. This had never been shown before in a peer-reviewed study. Grade B: direct tissue evidence; small n (9); open-label; DKD population; adipose and skin biopsy not necessarily representative of all tissue senescence.
12 patients with IPF, randomized 1:1 to D+Q vs placebo. Three weeks of D+Q (100 mg/1,250 mg, 3 consecutive days per week). Primary objective: adverse events and feasibility. Results: generally well-tolerated; no unanticipated serious adverse events; one SAE (edema and pleural effusion — possibly D+Q-related, causal relationship inconclusive). Feasibility for larger efficacy trials confirmed. The randomized placebo-controlled design addressed the open-label limitation of the 2019 study. This trial was not powered for efficacy — it confirmed safety signals and set the stage for Phase 2. Grade B: randomized; small n=12; safety endpoint only; IPF population.
Results presented 2024 [6]. Older women with low bone density randomized to D+Q vs control over multiple cycles. Primary bone density endpoint: not statistically significant for the overall group. Exploratory analysis: participants with higher baseline senescent cell burden showed significantly positive bone density response to D+Q — suggesting that the individual's senescent cell load may dictate clinical response. The overall failure to meet the primary endpoint for the whole group does not negate the hypothesis — it raises a more nuanced question about patient selection. Senior Mayo investigator comment (Fight Aging! blog, July 2024): 'Our exploratory analyses indicate that further studies are needed testing the hypothesis that the underlying senescent cell burden may dictate the clinical response to senolytics.' Grade B: Phase 2 RCT with mixed results; important signal for precision senolytic medicine.
THE HEALTHY AGING EVIDENCE GAP — THE CRITICAL MISSING TRIAL
All human D+Q trial data is from pathological populations with documented senescence-associated conditions: IPF (senescence-driven lung fibrosis), DKD (diabetes-related kidney disease with high senescent burden), osteoporosis (bone density loss associated with senescent cell accumulation). The community's primary use — senolytic clearance in healthy middle-aged adults for preventive healthspan extension — has not been studied. There is a compelling biological reason to expect D+Q would clear senescent cells in healthy adults: the DKD trial showed senescent cell reduction in human tissue, and healthy adults also accumulate senescent cells with age. Whether clearing those cells in otherwise-healthy people produces measurable healthspan benefit — improved physical function, reduced biological age, delayed disease onset — requires a trial in healthy adults. That trial does not yet exist.
Multiple Phase 2 trials are ongoing in Alzheimer's disease, diabetes, frailty, and other conditions. A schizophrenia/treatment-resistant depression trial protocol was published 2025 (PMC12120425). The D+Q clinical program is the most active and broad senolytic trial program globally. Results from these trials over 2026-2028 will substantially expand the human evidence base.
Trial
Indication
Status
Key Finding
IPF Phase 1 open-label
Idiopathic Pulmonary Fibrosis
Completed 2019
Physical function improvement; no control group
DKD Pilot
Diabetic Kidney Disease
Completed 2019
First direct human senescent cell reduction evidence; tissue biopsies
IPF Phase 1 RCT
Idiopathic Pulmonary Fibrosis
Completed 2023
Safety confirmed; feasibility established; one SAE
Osteoporosis Phase 2
Osteoporosis in older women
Completed 2024
Overall NS; high-senescent-burden subgroup positive signal
Multiple Phase 2 trials
Alzheimer's, frailty, diabetes, psychiatry
Ongoing 2026
Results expected 2026-2028
Safety is the most important section of this chapter because it addresses the gap between the clinical trial context (monitored, prescribed, drug-interaction-reviewed) and the community context (unmonitored, self-obtained, often without medical oversight). These two contexts produce meaningfully different risk profiles.
Dasatinib's adverse effect profile in the literature — the 11-24% pleural effusion rate, myelosuppression, QT prolongation data — comes from chronic daily dosing in CML patients (100 mg/day every day, indefinitely). The senolytic protocol uses 100 mg/day for 3 consecutive days, then weeks to months off. This is not the same pharmacological context. The intermittent protocol has a substantially better safety profile than chronic daily dosing: from all published D+Q senolytic trials combined, only one serious adverse event (one case of edema and pleural effusion with inconclusive causal relationship) has been documented. This is a meaningfully better safety profile than the CML literature would suggest. The intermittent senolytic protocol is, at the doses studied, much safer than chronic CML dosing. The community should understand both the clinical trial safety data (favorable) AND the FDA-labeled risks that apply to Dasatinib generally.
DASATINIB FDA-LABELED ADVERSE EFFECTS — KNOW THESE BEFORE USE
These are the documented adverse effects from Dasatinib's FDA prescribing information. Most refer to chronic daily dosing in CML patients — not the intermittent senolytic protocol. But they represent the compound's pharmacological risk potential, which applies at any dose when risk factors are present. FLUID RETENTION (including pleural effusion): Most common serious adverse effect; 11-24% in chronic CML use; one case in all D+Q senolytic trials combined. Symptoms: shortness of breath, dyspnea, cough, weight gain. QT PROLONGATION: Documented cardiac electrical conduction change; increased with CYP3A4 inhibitor co-administration. Symptoms: palpitations, irregular heartbeat, dizziness, syncope. ECG at baseline is the clinical standard. MYELOSUPPRESSION: Low white cells, red cells, platelets at high chronic doses; less common at senolytic intermittent dose. PULMONARY ARTERIAL HYPERTENSION: Rare; can develop months to years after starting; reversible if Dasatinib stopped. HEMORRHAGE: GI and CNS bleeding risk, particularly in patients on anticoagulants. HEPATOTOXICITY: Elevated liver enzymes; baseline LFTs recommended. PREGNANCY: Fetal harm documented; absolute contraindication.
The CYP3A4 interaction profile is the most practically important safety consideration for community users who are also taking other medications. Strong CYP3A4 inhibitors that dramatically increase Dasatinib plasma levels (contraindicated or requiring dose reduction in CML patients): ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir and other HIV protease inhibitors, nefazodone. Moderate CYP3A4 inhibitors (require caution): erythromycin, fluconazole, diltiazem, verapamil. GRAPEFRUIT JUICE: A documented clinically relevant CYP3A4 inhibitor — do not consume grapefruit or grapefruit juice while taking Dasatinib. Common medications in the community that may affect CYP3A4: simvastatin and lovastatin (actually CYP3A4 substrates, can be affected by Dasatinib in the other direction); fluoxetine (moderate CYP3A4 inhibitor); some herbal supplements including St. John's Wort (CYP3A4 inducer — reduces Dasatinib levels). Anyone taking any prescription medication should conduct a full drug interaction check before adding Dasatinib.
The clinical trials used: Baseline ECG (rule out QT prolongation); baseline CBC with differential (rule out baseline cytopenias); baseline comprehensive metabolic panel (liver function, renal function); medication reconciliation for CYP3A4 interactions; clinical assessment for active infections, bleeding risk, pulmonary symptoms. These are not optional formalities — they are the monitoring infrastructure that caught the one SAE in the senolytic trial program and that enables appropriate dose management. Community users who do not have access to this monitoring should not use Dasatinib.
Quercetin has an excellent safety profile at standard supplement doses. FDA GRAS status. No serious adverse events documented in the clinical senolytic trials for the quercetin component. Main considerations: mild GI discomfort at high doses; potential mild thyroid hormone metabolism effects at very high chronic doses; theoretical interaction with thyroid medications (separate from Dasatinib interaction). Quercetin at 1,000-1,250 mg/day as used in clinical trials is well-tolerated.
THE ACCESS PROBLEM MUST BE ADDRESSED FIRST
Dasatinib requires a prescription. The clinical trial protocol has been established at specific doses by Mayo Clinic researchers who monitored participants carefully. Community access routes include: (1) International pharmacy importation — legal gray area in the US for personal use; Dasatinib is available from Canadian, Mexican, and Indian pharmacies at substantially lower cost than US retail ($200-400 for 30 tablets vs $6,000-8,000 for 30 tablets US retail); (2) Longevity-oriented physician prescription — some progressive longevity medicine physicians will prescribe Dasatinib off-label for senolytic protocols with appropriate monitoring; (3) Compounding pharmacies — require prescription. The most appropriate path for community users: find a physician who practices functional/longevity medicine and can prescribe with appropriate monitoring. This is not a compound that should be used without medical access for the baseline monitoring described in Section 7.
Parameter
Clinical Trial Protocol
Notes
Dasatinib dose
100 mg/day
Same mg as daily CML dose, but intermittent — not chronic
Quercetin dose
1,000-1,250 mg/day
Standard quercetin dihydrate/capsule form; higher dose required for adequate bioavailability
Days on
3 consecutive days
Mon/Tue/Wed or other 3-day window
Cycle frequency
Every 3-4 weeks (varies by trial)
Some trials used monthly cycles for 3-6 months
Total cycles
3-6 cycles in different trials
Not established for healthy aging; duration unknown
Administration
Both oral, taken together in the morning
No specific food requirement; with food may reduce GI effects
Some community users follow quarterly rather than monthly cycles based on the hypothesis that senescent cell re-accumulation is slow enough that more frequent clearance is unnecessary. Some protocols use shorter cycles (2 days rather than 3). The clinical trial 3-day protocol is the only evidence-based duration. Community variations are untested.
If using standard quercetin dihydrate (most common): 1,000-1,250 mg/day — match the clinical trial doses to compensate for poor bioavailability. If using isoquercetin (quercetin 3-glucoside — better bioavailability): 500-750 mg/day may provide equivalent plasma exposure. If using quercetin phytosome: follow manufacturer dosing adjusted for 2-3x better bioavailability relative to standard. The most evidence-matched approach: standard quercetin at 1,000-1,250 mg/day, matching the clinical trial formulation and dose exactly.
Community reports during the active 3-day D+Q window: mild GI effects (nausea, loose stools) from Quercetin primarily; some fatigue during the Dasatinib portion; occasional mild flushing. Most community users describe the 3-day window as manageable. Symptoms resolve upon stopping. Monitor: breathing (any new shortness of breath warrants immediate discontinuation and medical evaluation for pleural effusion); heart rate and rhythm (palpitations or irregular heartbeat = stop and seek medical evaluation).
D+Q occupies a specific position in the longevity stack: it is a clearing intervention, not a building intervention. Its function is to eliminate senescent cells and reduce SASP-driven chronic inflammation. Its value in a stack is primarily temporal — it should precede compounds whose effects depend on a non-toxic, low-inflammation cellular environment.
FOXO4-DRI selectively kills senescent cells by disrupting the FOXO4-p53 interaction that prevents p53-driven apoptosis in senescent cells. D+Q kills senescent cells by disabling the pro-survival tyrosine kinase and BCL-2/PI3K networks. These mechanisms are complementary — they attack different survival defenses of senescent cells. Whether combining or alternating them produces better senescent cell clearance than either alone has not been studied. The theoretical argument for alternating rather than combining: different populations of senescent cells may be more responsive to one approach or the other; alternating cycles explores both mechanisms without creating excessive apoptotic burden simultaneously.
The most coherent longevity stack structure places D+Q (or FOXO4-DRI) first, followed by restorative compounds. The rationale: senescent cells and their SASP create a pro-inflammatory environment that suppresses stem cell function, impairs tissue repair, and potentially interferes with the signaling of restorative compounds. Clearing senescent cells first removes the SASP toxicity from the tissue microenvironment. Then: GHK-Cu, BPC-157, TB-500, NAD+ precursors, and mitochondrial compounds all operate in a more favorable cellular context after SASP reduction. The Humanin/IGF-1 inverse relationship is also relevant here — SASP-producing senescent cells upregulate CD38, which consumes NAD+. After D+Q clearance, CD38 activity should be lower, making NAD+ supplementation more effective (the CD38 inhibition stack from the NAD+ chapter becomes more potent in a lower-SASP environment).
Quercetin itself is a CD38 inhibitor — it reduces NAD+ consumption by CD38. When quercetin is taken as part of the D+Q senolytic protocol, it is briefly providing CD38 inhibition simultaneously with senolytic clearance. The 3-day protocol is too short for sustained NAD+ optimization, but the combination logic points toward: after a D+Q cycle, beginning or resuming NMN/NR supplementation in the lower-CD38-activity environment that cleared senescent tissue provides. The sequencing: D+Q cycle → wait 1-2 weeks → resume NAD+ precursor supplementation.
Compounds that interact with CYP3A4 (review the drug interactions in Section 7 before starting any cycle). Anticoagulants or antiplatelet agents — Dasatinib's platelet function impairment adds to bleeding risk. FOXO4-DRI in the same week — excessive simultaneous pro-apoptotic load. Any new supplement or medication started within 2 weeks of a D+Q cycle (allow time to assess tolerability before adding Dasatinib's complexity).
Mild GI effects; possible fatigue; no acute dramatic cognitive or physical changes expected during the 3-day window itself
Many community users and clinical trial participants report improved energy, reduced aches and joint pain, and general 'cleaner' subjective wellbeing. Clinical trials showed physical function improvements. SASP factor reductions occur in this window.
The window where clinical trial benefits were most measurable. Tissue-level senescent cell reduction confirmed in the DKD study. Physical function improvements documented in IPF patients. Community users report progressive improvement over multiple cycles.
No long-term (>6 month) controlled data from D+Q trials. Community reports of sustained benefit are consistent with the senolytic hypothesis — once cleared, senescent cell re-accumulation is gradual, and effects may persist between cycles.
Timeframe
Community / Clinical
Days 1-3 (active cycle)
Mild GI effects; possible fatigue; no acute dramatic cognitive or physical changes expected during the 3-day window itself
Days 4-14 (post-cycle week 1-2)
Many community users and clinical trial participants report improved energy, reduced aches and joint pain, and general 'cleaner' subjective wellbeing. Clinical trials showed physical function improvements. SASP factor reductions occur in this window.
Month 1-2 (after 2-3 cycles)
The window where clinical trial benefits were most measurable. Tissue-level senescent cell reduction confirmed in the DKD study. Physical function improvements documented in IPF patients. Community users report progressive improvement over multiple cycles.
Long-term
No long-term (>6 month) controlled data from D+Q trials. Community reports of sustained benefit are consistent with the senolytic hypothesis — once cleared, senescent cell re-accumulation is gradual, and effects may persist between cycles.
The path to appropriate D+Q use: (1) Identify a longevity medicine, functional medicine, or gerontology physician who is familiar with the senolytic literature; (2) Request baseline bloodwork: CBC with differential, CMP (liver function, creatinine), and baseline ECG; (3) Discuss current medications for CYP3A4 interactions; (4) Discuss personal/family history of QT prolongation, bleeding disorders, or active cancer; (5) Obtain prescription for Dasatinib — the physician can confirm appropriate dosing and cycle frequency; (6) Supplement quercetin at 1,000-1,250 mg/day of standard formulation alongside each Dasatinib dose.
The honest position on D+Q in 2026: the most evidence-backed senolytic intervention available, with direct human tissue evidence of senescent cell clearance and functional improvement in disease populations. The safety profile at intermittent senolytic doses is substantially better than chronic CML dosing but requires medical monitoring that the community is not receiving. The healthy aging application is compelling biologically and unvalidated clinically. The coming Phase 2 trial results will define whether D+Q becomes a standard clinical aging intervention or remains an experimental community protocol.
Baker DJ, Wijshake T, Tchkonia T, et al. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 479:232-236. [Genetic senescent cell clearance extends healthspan in mice — the foundational experiment establishing that senescent cell accumulation drives aging pathology, not just correlates with it]
Zhu Y, Tchkonia T, Pirtskhalava T, et al. (2015). The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 14(4):644-658. [Identification of D+Q as senolytics through systematic screen; selective senescent cell killing; improved physical function in aged and radiation-damaged mice; Kirkland/Mayo group — the compound discovery paper]
Justice JN, Nambiar AM, Tchkonia T, et al. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 40:554-563. [IPF Phase 1 open-label; physical function improvement in IPF patients; first human senolytic trial; Kirkland/Mayo group]
Hickson LJ, Langhi Prata LGP, Bobart SA, et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 47:446-456. PMC6796530. [DKD Phase 1 pilot; FIRST direct tissue evidence of senescent cell reduction in humans; adipose and skin biopsies; p16, p21, SA-β-gal all decreased; Kirkland/Mayo group]
Nambiar AM, et al. (2023) [5]. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine. [IPF Phase 1 RCT; n=12; safety primary endpoint; one SAE (edema/pleural effusion, inconclusive causation); feasibility confirmed for larger efficacy trials]
Results from a Phase 2 Trial of Senolytic Therapy Dasatinib and Quercetin for Osteoporosis. (2024). Fight Aging! coverage; Mayo Clinic Phase 2 results. [Osteoporosis older women; overall group NS for bone density; subgroup with high senescent burden showed positive signal; first Phase 2 D+Q results; suggests senescent cell burden may dictate clinical response]
Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. (2013) [7]. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 123(3):966-972. [Comprehensive review of cellular senescence and SASP; Kirkland group; foundational reference]
Sprycel (dasatinib) prescribing information. Bristol-Myers Squibb. [Complete FDA prescribing information; adverse effects, drug interactions, QT prolongation, pleural effusion, myelosuppression, PAH, pregnancy warnings; essential reference for any Dasatinib use]
D+Q is the most scientifically grounded senolytic intervention in existence. It is also the only compound in this book that genuinely requires a physician to use safely. Those two facts coexist without contradiction.
The central tension resolved: Dasatinib + Quercetin is not a community invention based on speculative biology. It was developed by Mayo Clinic researchers, backed by rigorous preclinical evidence, moved into humans through a systematic clinical trial program, and has produced the first direct tissue evidence that a pharmacological intervention reduces senescent cell burden in living humans. This is landmark science. The Geroscience Hypothesis — that clearing senescent cells improves human healthspan — has received its first human confirmation from this research program. No other senolytic combination has this evidence base. The community is correct to take D+Q seriously.
The problem is the gap between the clinical trial context and community self-administration. In the clinical trials: patients were selected by cardiologically appropriate QT intervals; CBC confirmed no baseline cytopenias; medication lists were reviewed for CYP3A4 interactions; physicians were available when the one SAE occurred. In community use: typically none of these safeguards exist. Dasatinib is a prescription oncology drug with FDA-labeled warnings for pleural effusion, QT prolongation, myelosuppression, and pulmonary arterial hypertension. The intermittent senolytic protocol has substantially less risk than chronic CML dosing. But 'substantially less than chemotherapy' and 'safe without monitoring' are not the same statement.
The healthy aging application — the community's primary motivation — is the most biologically compelling and least clinically validated aspect of D+Q use. The mechanism supports it perfectly: healthy middle-aged adults do accumulate senescent cells with age; clearing them should reduce chronic SASP-driven inflammation; the cascade of benefits documented in disease populations should apply, likely in attenuated form, in lower-burden healthy populations. Whether it does — and how much — requires clinical trials in healthy adults that do not yet exist.
D+Q is the most scientifically grounded senolytic intervention in existence. It is also the only compound in this book that genuinely requires a physician to use safely. Those two facts coexist without contradiction.
The central tension resolved: Dasatinib + Quercetin is not a community invention based on speculative biology. It was developed by Mayo Clinic researchers, backed by rigorous preclinical evidence, moved into humans through a systematic clinical trial program, and has produced the first direct tissue evidence that a pharmacological intervention reduces senescent cell burden in living humans. This is landmark science. The Geroscience Hypothesis — that clearing senescent cells improves human healthspan — has received its first human confirmation from this research program. No other senolytic combination has this evidence base. The community is correct to take D+Q seriously.
The problem is the gap between the clinical trial context and community self-administration. In the clinical trials: patients were selected by cardiologically appropriate QT intervals; CBC confirmed no baseline cytopenias; medication lists were reviewed for CYP3A4 interactions; physicians were available when the one SAE occurred. In community use: typically none of these safeguards exist. Dasatinib is a prescription oncology drug with FDA-labeled warnings for pleural effusion, QT prolongation, myelosuppression, and pulmonary arterial hypertension. The intermittent senolytic protocol has substantially less risk than chronic CML dosing. But 'substantially less than chemotherapy' and 'safe without monitoring' are not the same statement.
The healthy aging application — the community's primary motivation — is the most biologically compelling and least clinically validated aspect of D+Q use. The mechanism supports it perfectly: healthy middle-aged adults do accumulate senescent cells with age; clearing them should reduce chronic SASP-driven inflammation; the cascade of benefits documented in disease populations should apply, likely in attenuated form, in lower-burden healthy populations. Whether it does — and how much — requires clinical trials in healthy adults that do not yet exist.
D+Q is most appropriate for: adults over 50 with access to medical monitoring (ECG, CBC, drug interaction review), a physician willing to prescribe or oversee Dasatinib use, no significant contraindications (active bleeding, QT prolongation, CYP3A4 drug interactions, active malignancy without oncologist approval), and realistic expectations about benefit timelines and magnitude. The community use without medical monitoring — the most common real-world pattern — is pharmacologically risky in ways that the evidence genuinely supports worrying about.
Compound
Mechanism
Human Evidence
Access
Key Risk
Dasatinib + Quercetin
BCR-ABL/SRC TKI + BCL-2/PI3K inhibition
Grade B — direct human tissue evidence; multiple RCTs
Dasatinib: Rx only; Quercetin: OTC
QT prolongation, pleural effusion, CYP3A4 drug interactions
FOXO4-DRI
p53/FOXO4 disruption — senescent cell-specific
Grade D-E — animal data; no human trial
Research chemical; SubQ injection
Cancer concern (p53 disruption); no human data
GW501516 (Cardarine)
PPARδ agonism (NOT senolytic) — sometimes discussed with senolytics
Grade A (animal + human Phase 1/2)
Research chemical OTC
Multi-organ carcinogenicity; WADA banned
Fisetin
BCL-2/BCL-XL + PI3K/Akt + MDM2 inhibition (senolytic); SIRT1 activation, mTOR inhibition (non-senolytic)
Grade C — mouse lifespan extension (ITP FAILED to replicate); ex vivo human adipose; NO published in-vivo human senolytic data
OTC supplement — no prescription, no monitoring required
Poor oral bioavailability may limit senolytic efficacy; ITP failure; unpublished human trials
— End of Dasatinib + Quercetin —
THE PEPTIDE BIBLE | Dasatinib + Quercetin (D+Q) | For Research & Educational Purposes Only
Dasatinib + Quercetin (D+Q) is the most evidence-backed senolytic combination in existence and the first senolytic protocol tested in humans. Dasatinib: FDA-approved BCR-ABL/SRC family tyrosine kinase inhibitor (Sprycel, BMS); oral; MW 488 Da; standard CML dose 100 mg/day chronically; senolytic dose 100 mg/day for 3 consecutive days per cycle. PRESCRIPTION REQUIRED. Quercetin: naturally occurring flavonoid, OTC supplement, MW 302 Da; FDA GRAS; senolytic at 1,000-1,250 mg/day standard formulation. Mechanism: Dasatinib disables tyrosine kinase-dependent pro-survival networks in senescent preadipocytes and MSCs; Quercetin inhibits BCL-2/BCL-XL and PI3K/Akt survival pathways; together they cover complementary senescent cell populations. Both disable the pro-survival defenses that protect senescent cells from their own apoptotic environment. Senescence biology foundation: senescent cells accumulate with age due to increased induction + reduced immune clearance; SASP (pro-inflammatory secretome) drives chronic inflammation and age-related tissue pathology; clearing senescent cells reverses SASP-driven pathology in multiple animal models. Human evidence: IPF Phase 1 open-label (2019): physical function improvement in IPF patients. DKD pilot (2019): FIRST direct tissue evidence senescent cells decrease in humans (adipose + skin biopsy); p16, p21, SA-β-gal all reduced. IPF Phase 1 RCT (2023): safety confirmed; one SAE. Osteoporosis Phase 2 (2024): overall NS; subgroup with high senescent burden positive. Multiple Phase 2 trials ongoing (Alzheimer's, frailty, diabetes — results 2026-2028). HEALTHY ADULT EVIDENCE: ZERO — all trials in pathological populations. DASATINIB SAFETY: pleural effusion 11-24% (chronic CML dosing); one SAE in all D+Q senolytic trials; QT prolongation (ECG required); myelosuppression (CBC required); CYP3A4 drug interactions (grapefruit juice, azoles, macrolides, HIV antiretrovirals dramatically increase plasma levels); PAH (rare); hemorrhage (anticoagulant interaction); absolute contraindication in pregnancy. Protocol: D 100 mg + Q 1,000-1,250 mg, 3 consecutive days, then weeks-months off; repeat 3-6 cycles. WADA: neither compound listed. Access: Dasatinib international pharmacy import (gray area) or physician prescription + off-label. Minimum monitoring: baseline ECG, CBC, CMP, medication reconciliation for CYP3A4. The central tension: the only senolytic with real human evidence, requiring a prescription drug with documented cardiac and pulmonary risks, being used by a community without the medical monitoring that made the clinical trials safe.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.